Evidence map›Paper›PMID 37178383›Full record

ArticleNeurochemical research2023

The Regulation of GLT-1 Degradation Pathway by SIRT4.

Emre Yeşilören, Gizem Donmez Yalcin

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Emre YeşilörenDepartment of Medical Biology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, Turkey.ORCID http://orcid.org/0000-0002-4366-1074
Gizem Donmez YalcinDepartment of Medical Biology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, Turkey. gizem.yalcin@adu.edu.tr.ORCID http://orcid.org/0000-0002-5121-8232
Adnan Menderes University · TR

Funding

Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 221S145
6 · The paper itself

Abstract

Glial cells give rise to glioblastoma multiform as a primary brain tumor. In glioblastomas, neurons are destroyed via excitotoxicity which is the accumulation of excess glutamate in synaptic cavity. Glutamate Transporter 1 (GLT-1) is the main transporter that absorbs the excessive glutamate. Sirtuin 4 (SIRT4) was shown to have a potential protective role against excitotoxicity in previous studies. In this study, the regulation of dynamic GLT-1 expression by SIRT4 was analyzed in glia (immortalized human astrocytes) and glioblastoma (U87) cells. The expression of GLT-1 dimers and trimers were reduced and the ubiquitination of GLT-1 was increased in glioblastoma cells when SIRT4 was silenced; however GLT-1 monomer was not affected. In glia cells, SIRT4 reduction did not affect GLT-1 monomer, dimer, trimer expression or the ubiquitination of GLT-1. The phosphorylation of Nedd4-2 and the expression of PKC did not change in glioblastoma cells when SIRT4 was silenced but increased in glia cells. We also showed that SIRT4 deacetylates PKC in glia cells. In addition, GLT-1 was shown to be deacetylated by SIRT4 which might be a priority for ubiquitination. Therefore, we conclude that GLT-1 expression is regulated differently in glia and glioblastoma cells. SIRT4 activators or inhibitors of ubiquitination may be used to prevent excitotoxicity in glioblastomas.

Indexed as

Excitatory Amino Acid Transporter 2GlioblastomaSirtuinsAstrocytesGlutamic AcidHumansMitochondrial ProteinsNeuronsProteolysisUbiquitinationExcitatory Amino Acid Transporter 2Glutamic AcidMitochondrial ProteinsSIRT4 protein, humanSirtuinsGlioblastomaGLT-1Nedd4-2SIRT4Ubiquitin

Identifiers

PMID37178383
OpenAlexW4376504698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.